IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018
November 26, 2018 16:35 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will present data on its DPX-RSV...
IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer
November 20, 2018 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Nov. 20, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced an amendment to its phase 1b/2 clinical...
IMV Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
November 15, 2018 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Nov. 15, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors...
Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors
November 06, 2018 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has appointed seasoned...
IMV Inc. Announces Q3 2018 Financial Results and Investor Conference Call Details
November 02, 2018 07:05 ET
|
IMV Inc.
Achieved Initial Positive Data from Phase 2 Clinical Trial in DLBCL with MerckEntered into Collaboration with Merck on Phase 2 Basket Trial Across Five IndicationsAttained Multiple Milestones in...
IMV Inc. to Announce Third Quarter 2018 Financial Results and Host Earnings Call on November 2, 2018
October 23, 2018 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a...
IMV Inc. to Present at Upcoming Investor Conferences
October 09, 2018 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors...
IMV Provides Update on Progress of its DPX-RSV Program
September 27, 2018 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Sept. 27, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced results of ongoing research to further...
IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial of Lead Candidate DPX-Survivac in Combination with Merck’s Keytruda® in Patients with DLBCL
September 18, 2018 07:05 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Sept. 18, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced details of the initial data from an ongoing...
IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications
September 11, 2018 07:05 ET
|
IMV Inc.
HALIFAX, Nova Scotia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has expanded its clinical program...